First time I've gotten useful info from Google's Chat Bot:
Some drugs that have been approved as part of an open-label extension (OLE) include: Radicava/Edaravone, Neudexta, Riluzole/Tiglutik. The FDA approved Relyvrio (AMX0035) in 2022 for the treatment of ALS. Relyvrio is a combination of sodium phenylbutyrate and taurursodiol that can prevent nerve cell death by blocking stress signals. In 2023, the FDA approved Qalsody (tofersen) for use to treat SOD1-ALS. Qalsody is the first drug developed for patients with a rare form of ALS caused by mutations in a gene called SOD1.
my adviser also told me with this trial RETT DATA should be enough to get approval.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS